New urate-lowing therapies
A Abhishek - Current Opinion in Rheumatology, 2018 - journals.lww.com
New urate-lowing therapies : Current Opinion in Rheumatology New urate-lowing therapies :
Current Opinion in Rheumatology Log in or Register Subscribe to journalSubscribe Get new …
Current Opinion in Rheumatology Log in or Register Subscribe to journalSubscribe Get new …
Green stability-indicating capillary electrophoretic method for simultaneous determination of Lesinurad and Allopurinol in tablet dosage form: degradation kinetics …
A binary mixture of Lesinurad (LES) and Allopurinol (ALP) is a newly marketed anti-gout
combination where no stability indicating methods have been reported for its analysis. In this …
combination where no stability indicating methods have been reported for its analysis. In this …
[PDF][PDF] Pharmacological overview for therapy of gout and hyperuricemia
Hyperuricemia & gout are disease conditions marked by over production and reduced
excretion of uric acid. These conditions are linked with unhealthy lifestyle, Hypertension …
excretion of uric acid. These conditions are linked with unhealthy lifestyle, Hypertension …
Establishment of Polydopamine-Modified HK-2 Cell Membrane Chromatography and Screening of Active Components from Plantago asiatica L.
H Gao, Z Liu, F Song, J Xing, Z Zheng, Z Hou… - International Journal of …, 2024 - mdpi.com
Cell membrane chromatography (CMC) has been widely recognized as a highly efficient
technique for in vitro screening of active compounds. Nevertheless, conventional CMC …
technique for in vitro screening of active compounds. Nevertheless, conventional CMC …
Zurampic protects pancreatic β-cells from high uric acid induced-damage by inhibiting URAT1 and inactivating the ROS/AMPK/ERK pathways
X Ying, K Wang, Z Jia, T Xu, Q Xu… - Cellular Physiology …, 2018 - search.proquest.com
Background/Aims: Zurampic is a US FDA approved drug for treatment of gout. However, the
influence of Zurampic on pancreatic β-cells remains unclear. The study aimed to evaluate …
influence of Zurampic on pancreatic β-cells remains unclear. The study aimed to evaluate …
Chromatographic determination of allopurinol and lesinurad simultaneously in raw and tablet forms.
T Sravanthi, N Madhavi - Drug invention today, 2020 - search.ebscohost.com
Objective: A novel stability-indicating high-pressure liquid chromatography procedure was
developed followed by validation for the simultaneous estimation of allopurinol and …
developed followed by validation for the simultaneous estimation of allopurinol and …
Determination of lesinurad in rat plasma by a UHPLC–MS/MS assay
XY Zhou, LJ Yuan, Z Chen, PF Tang, XY Li… - Chemistry Central …, 2017 - Springer
Lesinurad is an oral inhibitor of urate-anion exchanger transporter 1 and has been approved
by the US Food and Drug Administration for combination therapy with a xanthine oxidase …
by the US Food and Drug Administration for combination therapy with a xanthine oxidase …
[HTML][HTML] Lesinurad Therapy and CYP2C9 genotype
L Dean - 2019 - europepmc.org
Lesinurad (brand name Zurampic) is a urate transport inhibitor used in the treatment of gout.
Gout is one of the most common types of inflammatory arthritis, affecting approximately 3 …
Gout is one of the most common types of inflammatory arthritis, affecting approximately 3 …
Multiwavelength UV-metric and pH-metric determination of the multiple dissociation constants of the Lesinurad
M Meloun, A Čápová, L Pilařová, T Pekárek - Journal of Pharmaceutical …, 2018 - Elsevier
Potentiometric and spectrophotometric pH-titrations of the lesinurad for three consecutive
dissociation constants determination were compared. Lesinurad is a selective inhibitor of …
dissociation constants determination were compared. Lesinurad is a selective inhibitor of …
基于指南的痛风诊治进展
曹雯， 陈国芳， 刘超 - 中国全科医学, 2018 - chinagp.net
随着对痛风研究的不断深入, 2016—2017 年发布了《 英国风湿病学会(BSR) 痛风管理指南》 和《
美国临床医师协会(ACP) 临床实践指南: 急性和复发性痛风管理》, 包括对痛风的诊断 …
美国临床医师协会(ACP) 临床实践指南: 急性和复发性痛风管理》, 包括对痛风的诊断 …